Alteration of endothelial proteoglycan and heparanase gene expression by high glucose, insulin and heparin.
Heparan sulfate proteoglycans (HSPGs) contain a core protein with glycosaminoglycans attached. Reduced glycosaminoglycan, in endothelial HSPGs syndecan and perlecan, is associated with diabetic cardiovascular complications but changes in core protein remain controversial. Since heparanase degrades heparan sulfate, we wished to determine if changes in endothelial heparanase mRNA, by high glucose (HG), correlate with changes in syndecan and perlecan core proteins, and to observe effects of heparin or insulin. RNA was isolated from cultured human aortic endothelial cells treated with HG (30mM), insulin (0.01 units/mL), heparin (0.5μg/mL), HG plus heparin and/or insulin for 24h. Real time PCR revealed that HG alone significantly increased heparanase, decreased syndecan with no effect on perlecan mRNA. Heparin or insulin significantly prevented the increase in heparanase but decreased perlecan mRNA while heparin, but not insulin, prevented the decrease in syndecan mRNA in HG treated cells. HG plus heparin and insulin increased heparanase and syndecan mRNA compared to all other treatments and decreased perlecan mRNA compared to control and HG alone. Heparin may protect endothelium from HG injury by reducing heparanase and increasing syndecan while insulin inhibits heparanase expression. Effects with insulin plus heparin suggest interference in transcriptional regulation of heparanase and syndecan genes.
Department of Veterinary Biomedical Sciences, University of Saskatchewan, Saskatoon, Saskatchewan, S7N 5B4, Canada.
J
J
Han
L M
LM
Hiebert
D001011:Aorta / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D005947:Glucose / Q000494:pharmacology; D005966:Glucuronidase / Q000235:genetics*; D019812:Heparan Sulfate Proteoglycans / Q000378:metabolism; D006493:Heparin / Q000494:pharmacology*; D006497:Heparan Sulfate / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000494:pharmacology*; D011509:Proteoglycans / Q000235:genetics*; D012333:RNA, Messenger / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D053667:Syndecans / Q000235:genetics; D000099175:Heparanase
D005947:Glucose; D005966:Glucuronidase; D019812:Heparan Sulfate Proteoglycans; D006493:Heparin; D006497:Heparan Sulfate; D007328:Insulin; D011509:Proteoglycans; D012333:RNA, Messenger; D053667:Syndecans; D000099175:Heparanase; C071927:perlecan
C(T); CMF-DPBS; Calcium and magnesium-free Dulbecco's phosphate-buffered saline; Diabetic cardiovascular complications; ECM; ECs; Endothelial cells; Extracellular matrix; GAGs; Glycosaminoglycans; HAECs; HS; HSPGs; Heparan sulfate; Heparan sulfate proteoglycans; Heparanase; Heparin; Human aortic endothelial cells; PAECs; Porcine aortic endothelial cells; Syndecan; Threshold cycle